VistaGen is a biotech company applying its human pluripotent stem cell (hPSC) technology for drug rescue, including predictive toxicology and drug metabolism screening.
The company's human pluripotent stem cell (hPSC) technology platform, Human Clinical Trials in a Test Tube™, is based upon a combination of the company's proprietary and exclusively licensed hPSC technologies.
The platform assesses the toxicity and metabolism (drug-drug interaction) profile of new small molecule drug candidates applicable to a wide range of diseases and conditions. The platform is designed to work at an accelerated and more precise rate than non-clinical in vitro techniques and technologies currently used by biotechnology and pharmaceutical companies.
Among other products, AV-101 is VistaGen's novel, orally available prodrug candidate for the treatment of neuropathic pain, depression, and potentially other neurological conditions.
In preclinical studies, AV-101 demonstrated positive levels of oral bioavailability, rapid and efficient transport across the blood-brain barrier, and preferential conversion into 7-CKYNA at the site of seizures and potential neural damage in the brain and spinal cord.
The candidate has undergone successful phase 1 development, funded by an $8.8 million grant from the U.S. National Institutes of Health, under an active Investigational New Drug (NYSE:IND) application with the U.S. FDA.
For more information, visit vistagen.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com